Clinical trials: Covid19 Vaccination
Cancer
(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
Patients with cancer are considered vulnerable to severe acute respiratory syndrome coronavirus 2 infection and have been prioritized in the vaccination process in several countries, including Taiwan.
- Trial name
- NCT05384509
- Testing
- solid organ malignancies treatment
- Where
- Taiwan
- Volunteers
- 320 people
- Sponsor
- Chang Gung Memorial Hospital
Respiratory Tract Infections, Covid19
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
On March 11 2020 the World Health Organization (WHO) declared the coronavirus (SARS-CoV-2) outbreak a pandemic. Worldwide, the number of confirmed cases continues to rise, leading to significant morbidity and mortality.
- Trial name
- BCG-PRIME (NCT04537663)
- Testing
- Bacille Calmette-Guérin (BCG)
- Where
- 20 sites in Netherlands
- Volunteers
- 6,112 people
- Sponsor
- UMC Utrecht
SARS-CoV Infection
SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel Following mRNA COVID-19 Vaccination
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT04880174
- Testing
- serological testing
- Where
- Belgium
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
COVID-19
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with…
- Trial name
- NCT05343871
- Testing
- Sinovac, AZD1222, BNT162b2
- Where
- 2 sites in Brazil, Pakistan
- Volunteers
- 2,354 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Systemic Lupus
Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus
The main objective is to study the impact of vaccination against Covid-19 on the specific humoral and cellular immune response (against SARS-CoV-2) and non-specific (evolution of the pathological immune system of the disease), in…
- Trial name
- LUPCELLVAX (NCT04894253)
- Testing
- SRAS-CoV-2 vaccination immunological response
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19, Vaccine Hesitancy
Addressing COVID-19 Vaccine Hesitancy With Muliti-Level Interventions in Appalachia
The purpose of this community-engaged study is to test the ability of county-level strategies to increase uptake of COVID-19 vaccination.
- Trial name
- K-VAC (NCT06505993)
- Testing
- Health Communication, Health Communication + Structural
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Marc Kiviniemi
COVID-19 Vaccination
Community Care Intervention to Decrease COVID-19 Vaccination Inequities
The purpose of this study is to find out if a community health workers (CHW) intervention conducted in Federally Qualified Health Centers (FQHCs) can increase the number of adults with chronic illnesses who are up-to-date with…
- Trial name
- NCT06156254
- Testing
- Community Health Worker Intervention to Enhance Vaccination Behavior (CHW-VB)
- Where
- 4 sites in United States
- Volunteers
- 800 people
- Sponsor
- RAND
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis
Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and…
- Trial name
- VACOVAJI (NCT05547451)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Nantes University Hospital
SARS-CoV2 Infection, Vaccine Reaction
Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines
Patients who voluntarily visit vaccination centers in Greece against COVID-19 are recruited and their immunization levels against Sars-Cov2 are assesed by measurement of the levels of serum antibodies against Sars-cov-2 before…
- Trial name
- NCT04954651
- Testing
- Approved vaccines against Sars-Cov2
- Where
- Greece
- Volunteers
- 1,000 people
- Sponsor
- University of Patras
Cancer
Responses to COVID-19 Vaccination in Patients With Cancer
This is an observational study that will prospectively record and monitor responses and clinical outcomes of patients with cancer after covid-19 vaccination, including measurements of antibody titers in serum and also record…
- Trial name
- ReCOVer (NCT04745377)
- Testing
- IgG neutralising antibody titers to S1 and S2 proteins of SARS-COV-2 virus
- Where
- Greece
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- Hellenic Cooperative Oncology Group
CLL, Multiple Myeloma
The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
The corona pandemic is a continuing global challenge due to Corona Virus 2019 (COVID-19). The purpose of the study is to evaluate the capability of Haemato-oncology patients to generate antibodies against COVID-19 after infection…
- Conditions
- CLL, Multiple Myeloma, Lymphoma
- Trial name
- NCT04746092
- Where
- Israel
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Vaccine Refusal
Understanding and Overcoming the Racial/Ethnic Inequalities in COVID-19 Vaccination Acceptance
With the constant threat of new epidemic waves and the emergence of variants, COVID-19 resilience can only be attained when a sufficient level of immunity is achieved.
- Trial name
- NCT05238428
- Testing
- Trust boost
- Where
- United Kingdom
- Volunteers
- 4,039 people, healthy volunteers welcome
- Sponsor
- University of Essex
COVID 19 Vaccine
Third Dose of mRNA Vaccination to Boost COVID-19 Immunity (mBoost Study)
300 adults ≥30 years of age who have previously received two doses of an inactivated COVID-19 vaccine at least 3 months earlier will receive a third dose with an mRNA vaccine (BNT162b2, BioNTech).
- Trial name
- NCT05057182
- Testing
- BNT162b2
- Where
- Hong Kong
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Covid19, BCG Vaccination Reaction
Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland
Countries that have not carried out universal mass vaccination against tuberculosis (BCG) have been shown to have higher incidence and death rates due to COVID-19 than countries with mass, long-term BCG immunization programmes.
- Conditions
- Covid19, BCG Vaccination Reaction, SARS-CoV Infection
- Trial name
- NCT04648800
- Testing
- BCG-10 vaccine, 0.9% saline
- Where
- 6 sites in Poland
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Hanna Czajka
COVID-19, Influenza
Equity Evaluation of Fact Boxes on Informed COVID-19 and Influenza Vaccination Decisions - Study Protocol
The study aims to evaluate whether evidence-based fact boxes on COVID-19 and influenza vaccination contribute to the decision making of laypeople from different social backgrounds in different educational settings (e.g.
- Trial name
- NCT06076421
- Testing
- Fact box
- Where
- Germany
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Harding Center for Risk Literacy
COVID-19 Vaccination
Developing and Testing a COVID-19 Vaccination Acceptance Intervention
The COVID-19 pandemic has resulted in significant loss of life and suffering with total case and death counts increasing daily, particularly with the emergence of the delta variant.
- Trial name
- CoVAcS (NCT05027464)
- Testing
- Moving to COVID-19 Vaccine Acceptance Intervention
- Where
- 2 sites in United States
- Volunteers
- 338,718 people
- Sponsor
- VA Office of Research and Development
SARS-CoV-2, COVID-19 Vaccine
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
This is a randomized, blinded, and dose escalation phase I trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT06167915
- Testing
- 30μg dose of LYB002V14, 60μg dose of LYB002V14
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
Individual Satisfaction, Pain Management
The Effect on Pain and Satisfaction of Two Different Non-Pharmacological Methods Used During Coronavirus (Covid-19) Vaccination
The aim of this study was to determine the effect on pain and satisfaction during the administration of Covid-19 vaccination of two different non-pharmacological methods: squeezing a stress ball and placing Buzzy® on the…
- Trial name
- NCT05514262
- Testing
- The stress ball, The Buzzy® device
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Uludag University
Quality of Life, Injection Site Reaction
Simultaneous mRNA COVID-19 and IIV4 Vaccination Study
This study is a prospective, randomized clinical trial. During this study, participants will be randomly assigned to receive quadrivalent inactivated influenza vaccine (IIV4) and mRNA COVID-19 vaccine either simultaneously or…
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Trial name
- NCT05028361
- Testing
- mRNA COVID-19, IIV4
- Where
- 3 sites in United States
- Volunteers
- 348 people, healthy volunteers welcome
- Sponsor
- Duke University
Antiphospholipid Syndrome, COVID-19 Infection
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
Prospective observational study to evaluate a possible change in APS antibody profiles after COVID-19 infection or vaccination
- Conditions
- Antiphospholipid Syndrome, COVID-19 Infection, COVID-19 Vaccination
- Trial name
- APSantiCo (NCT05313048)
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Cardioangiologisches Centrum Bethanien